腾盛博药
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum 2022-09-01 07:30
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results 2022-08-24 07:30
Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head 2022-08-23 07:30
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants 2022-07-27 07:00
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China 2022-07-19 12:34
Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer 2022-07-13 19:00
Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China 2022-07-07 07:10
Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China 2022-07-04 07:10
Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China 2022-06-09 19:00
Brii Biosciences to be Added to MSCI China Small Cap Index 2022-05-25 08:00
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant 2022-05-09 19:46
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report 2022-05-07 09:00
Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022 2022-03-31 18:05
Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China 2022-03-30 08:05
Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results 2022-03-23 07:20
Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition) 2022-03-16 09:00
Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources 2022-01-27 21:00
Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B 2021-12-27 18:45
Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant 2021-12-12 18:50
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China 2021-12-09 06:10
1 2 3